ReP USP - Resultado da busca

Artigo de periodico
Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies (2020)
Staquicini, Fernanda I; Tang, Fenny Hui Fen; Smith, Tracey L; Gelovani, Juri G; Giordano, Ricardo José ; Libutti, Steven K; Sidman, Richard L; Cavenee, Webster K; Arap, Wadih; Pasqualini, Renata
Source: Cancer Gene Therapy. Unidade: IQ
Subjects: NEOPLASIAS, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STAQUICINI, Fernanda I et al. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Therapy, v. 27, p. 301–310, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41417-019-0101-2. Acesso em: 19 ago. 2024.
APA
Staquicini, F. I., Tang, F. H. F., Smith, T. L., Gelovani, J. G., Giordano, R. J., Libutti, S. K., et al. (2020). Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Therapy, 27, 301–310. doi:10.1038/s41417-019-0101-2
NLM
Staquicini FI, Tang FHF, Smith TL, Gelovani JG, Giordano RJ, Libutti SK, Sidman RL, Cavenee WK, Arap W, Pasqualini R. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies [Internet]. Cancer Gene Therapy. 2020 ; 27 301–310.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0101-2
Vancouver
Staquicini FI, Tang FHF, Smith TL, Gelovani JG, Giordano RJ, Libutti SK, Sidman RL, Cavenee WK, Arap W, Pasqualini R. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies [Internet]. Cancer Gene Therapy. 2020 ; 27 301–310.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0101-2
Artigo de periodico
HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate (2020)
Ruckert, Mariana Tannús ; Brouwers-Vos, Annet Z.; Nagano, Luis Fernando ; Schuringa, Jan Jacob; Silveira, Vanessa da Silva
Source: Cancer Gene Therapy. Unidade: FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, PROLIFERAÇÃO CELULAR, DIFERENCIAÇÃO CELULAR, CÉLULAS-TRONCO, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RUCKERT, Mariana Tannús et al. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate. Cancer Gene Therapy, v. 27, n. 11-12, p. 830-833, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41417-020-0198-3. Acesso em: 19 ago. 2024.
APA
Ruckert, M. T., Brouwers-Vos, A. Z., Nagano, L. F., Schuringa, J. J., & Silveira, V. da S. (2020). HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate. Cancer Gene Therapy, 27( 11-12), 830-833. doi:10.1038/s41417-020-0198-3
NLM
Ruckert MT, Brouwers-Vos AZ, Nagano LF, Schuringa JJ, Silveira V da S. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate [Internet]. Cancer Gene Therapy. 2020 ; 27( 11-12): 830-833.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-020-0198-3
Vancouver
Ruckert MT, Brouwers-Vos AZ, Nagano LF, Schuringa JJ, Silveira V da S. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate [Internet]. Cancer Gene Therapy. 2020 ; 27( 11-12): 830-833.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-020-0198-3
Artigo de periodico
Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression (2020)
Magalhães, Taciani de Almeida ; Cruzeiro, Gustavo Alencastro Veiga ; Sousa, Graziella Ribeiro de ; Silva, Keteryne Rodrigues da ; Lira, Régia Caroline Peixoto ; Scrideli, Carlos Alberto ; Tone, Luiz Gonzaga ; Valera, Elvis Terci ; Borges, Kleiton Silva
Source: Cancer Gene Therapy. Unidades: FMRP, FCFRP
Subjects: CONTAGEM DE ESPERMATOZOIDES, ESPERMATOZOIDES, TESTÍCULO, RATOS WISTAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGALHÃES, Taciani de Almeida et al. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression. Cancer Gene Therapy, v. 27, n. 6, p. 509-512, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41417-019-0122-x. Acesso em: 19 ago. 2024.
APA
Magalhães, T. de A., Cruzeiro, G. A. V., Sousa, G. R. de, Silva, K. R. da, Lira, R. C. P., Scrideli, C. A., et al. (2020). Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression. Cancer Gene Therapy, 27( 6), 509-512. doi:10.1038/s41417-019-0122-x
NLM
Magalhães T de A, Cruzeiro GAV, Sousa GR de, Silva KR da, Lira RCP, Scrideli CA, Tone LG, Valera ET, Borges KS. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression [Internet]. Cancer Gene Therapy. 2020 ; 27( 6): 509-512.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0122-x
Vancouver
Magalhães T de A, Cruzeiro GAV, Sousa GR de, Silva KR da, Lira RCP, Scrideli CA, Tone LG, Valera ET, Borges KS. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression [Internet]. Cancer Gene Therapy. 2020 ; 27( 6): 509-512.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0122-x
Artigo de periodico
CTGF expression is indicative of better survival rates in patients with medulloblastoma (2020)
Cruzeiro, Gustavo Alencastro Veiga ; Lira, Régia Caroline Peixoto ; Magalhães, Taciani de Almeida ; Scrideli, Carlos Alberto ; Valera, Elvis Terci ; Baumgartner, Martin; Tone, Luiz Gonzaga
Source: Cancer Gene Therapy. Unidade: FMRP
Subjects: MEDULOBLASTOMA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRUZEIRO, Gustavo Alencastro Veiga et al. CTGF expression is indicative of better survival rates in patients with medulloblastoma. Cancer Gene Therapy, v. 27, n. 5, p. 378-382, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41417-019-0100-3. Acesso em: 19 ago. 2024.
APA
Cruzeiro, G. A. V., Lira, R. C. P., Magalhães, T. de A., Scrideli, C. A., Valera, E. T., Baumgartner, M., & Tone, L. G. (2020). CTGF expression is indicative of better survival rates in patients with medulloblastoma. Cancer Gene Therapy, 27( 5), 378-382. doi:10.1038/s41417-019-0100-3
NLM
Cruzeiro GAV, Lira RCP, Magalhães T de A, Scrideli CA, Valera ET, Baumgartner M, Tone LG. CTGF expression is indicative of better survival rates in patients with medulloblastoma [Internet]. Cancer Gene Therapy. 2020 ; 27( 5): 378-382.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0100-3
Vancouver
Cruzeiro GAV, Lira RCP, Magalhães T de A, Scrideli CA, Valera ET, Baumgartner M, Tone LG. CTGF expression is indicative of better survival rates in patients with medulloblastoma [Internet]. Cancer Gene Therapy. 2020 ; 27( 5): 378-382.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/s41417-019-0100-3
Artigo de periodico
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma (2013)
Pezuk, J. A.; Brassesco, M. S.; Morales, Andressa Gois; Oliveira, J. C. de; Queiroz, Rosane Gomes de Paula; Machado, Hélio Rubens; Carlotti Júnior, Carlos Gilberto; Serafini, Luciano Neder; Scrideli, Carlos Alberto; Tone, Luiz Gonzaga
Source: Cancer Gene Therapy. Unidades: IB, FMRP
Subjects: ASTROCITOMA, PROTEÍNAS QUINASES, CICLO CELULAR, INIBIDORES DE ENZIMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEZUK, J. A. et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Therapy, v. 20, n. 9, p. 499-506, 2013Tradução . . Disponível em: https://doi.org/10.1038/cgt.2013.46. Acesso em: 19 ago. 2024.
APA
Pezuk, J. A., Brassesco, M. S., Morales, A. G., Oliveira, J. C. de, Queiroz, R. G. de P., Machado, H. R., et al. (2013). Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Therapy, 20( 9), 499-506. doi:10.1038/cgt.2013.46
NLM
Pezuk JA, Brassesco MS, Morales AG, Oliveira JC de, Queiroz RG de P, Machado HR, Carlotti Júnior CG, Serafini LN, Scrideli CA, Tone LG. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma [Internet]. Cancer Gene Therapy. 2013 ; 20( 9): 499-506.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2013.46
Vancouver
Pezuk JA, Brassesco MS, Morales AG, Oliveira JC de, Queiroz RG de P, Machado HR, Carlotti Júnior CG, Serafini LN, Scrideli CA, Tone LG. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma [Internet]. Cancer Gene Therapy. 2013 ; 20( 9): 499-506.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2013.46
Artigo de periodico
Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model (2012)
Chaves, K. C. B.; Peron, Jean Pierre Schatzmann ; Chammas, R.; Turaça, L. T.; Pesquero, J. B.; Braga, M. S.; Foguer, K.; Schor, N.; Bellini, M. H.
Source: Cancer Gene Therapy. Unidade: FM
Subjects: IMUNOTERAPIA, DNA, CARCINOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHAVES, K. C. B. et al. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Cancer Gene Therapy, v. 19, n. 8, p. 558-565, 2012Tradução . . Disponível em: https://doi.org/10.1038/cgt.2012.32. Acesso em: 19 ago. 2024.
APA
Chaves, K. C. B., Peron, J. P. S., Chammas, R., Turaça, L. T., Pesquero, J. B., Braga, M. S., et al. (2012). Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Cancer Gene Therapy, 19( 8), 558-565. doi:10.1038/cgt.2012.32
NLM
Chaves KCB, Peron JPS, Chammas R, Turaça LT, Pesquero JB, Braga MS, Foguer K, Schor N, Bellini MH. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model [Internet]. Cancer Gene Therapy. 2012 ; 19( 8): 558-565.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2012.32
Vancouver
Chaves KCB, Peron JPS, Chammas R, Turaça LT, Pesquero JB, Braga MS, Foguer K, Schor N, Bellini MH. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model [Internet]. Cancer Gene Therapy. 2012 ; 19( 8): 558-565.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2012.32
Artigo de periodico
Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck (2008)
Michaluart, P.; Abdallah, K. A.; Lima, F. D.; Smith, R.; Moysés, R. A.; Coelho, V.; Victora, G. D.; Socorro-Silva, A.; Volsi, E. C.; Zárate-Bladés, C. R.; Ferraz, Alberto Rossetti; Barreto, A. K.; Chammas, M. C.; Gomes, R.; Gebrim, E.; Arakawa-Sugueno, L.; Fernandes, K. P.; Lotufo, Paulo Andrade; Cardoso, M. R.; Kalil, J.; Silva, Célio Lopes
Source: Cancer Gene Therapy. Unidades: HU, FMRP, FSP
Subjects: IMUNOTERAPIA, DNA, CARCINOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MICHALUART, P. et al. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Therapy, v. 15, n. 10, p. 676-684, 2008Tradução . . Disponível em: https://doi.org/10.1038/cgt.2008.35. Acesso em: 19 ago. 2024.
APA
Michaluart, P., Abdallah, K. A., Lima, F. D., Smith, R., Moysés, R. A., Coelho, V., et al. (2008). Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Therapy, 15( 10), 676-684. doi:10.1038/cgt.2008.35
NLM
Michaluart P, Abdallah KA, Lima FD, Smith R, Moysés RA, Coelho V, Victora GD, Socorro-Silva A, Volsi EC, Zárate-Bladés CR, Ferraz AR, Barreto AK, Chammas MC, Gomes R, Gebrim E, Arakawa-Sugueno L, Fernandes KP, Lotufo PA, Cardoso MR, Kalil J, Silva CL. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck [Internet]. Cancer Gene Therapy. 2008 ; 15( 10): 676-684.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2008.35
Vancouver
Michaluart P, Abdallah KA, Lima FD, Smith R, Moysés RA, Coelho V, Victora GD, Socorro-Silva A, Volsi EC, Zárate-Bladés CR, Ferraz AR, Barreto AK, Chammas MC, Gomes R, Gebrim E, Arakawa-Sugueno L, Fernandes KP, Lotufo PA, Cardoso MR, Kalil J, Silva CL. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck [Internet]. Cancer Gene Therapy. 2008 ; 15( 10): 676-684.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/cgt.2008.35
Artigo de periodico
A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition (2005)
Strauss, Bryan Eric; Bajgelman, Márcio Chaim; Costanzi-Strauss, Eugenia
Source: Cancer Gene Therapy. Unidade: ICB
Assunto: HISTOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STRAUSS, Bryan Eric e BAJGELMAN, Márcio Chaim e COSTANZI-STRAUSS, Eugenia. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Therapy, v. 12, p. 935-946, 2005Tradução . . Disponível em: https://doi.org/10.1038/sj.cgt.7700846. Acesso em: 19 ago. 2024.
APA
Strauss, B. E., Bajgelman, M. C., & Costanzi-Strauss, E. (2005). A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Therapy, 12, 935-946. doi:10.1038/sj.cgt.7700846
NLM
Strauss BE, Bajgelman MC, Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition [Internet]. Cancer Gene Therapy. 2005 ; 12 935-946.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/sj.cgt.7700846
Vancouver
Strauss BE, Bajgelman MC, Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition [Internet]. Cancer Gene Therapy. 2005 ; 12 935-946.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1038/sj.cgt.7700846

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation